REGENXBIO Inc.
HealthcareNASDAQ:RGNX · NASDAQ Global Select
+$0.38 today
Vol 0.90M · Avg 1.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-188.7%
avg -47.1%
ROIC
-42.1%
avg -28.4%
ROA
-42.8%
avg -23.6%
Analysis
ROIC is currently the strongest return metric at -42.1% versus its period average of -28.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Curran Simpson | President, Chief Executive Officer & Director | $1.07M | — | 64 | $233,651.00 | 0.45% |
Patrick J. Christmas | Executive Vice President & Chief Strategy and Legal Officer | $944,701.00 | — | 55 | $210,667.00 | 0.41% |
Stephen Pakola | Executive Vice President & Chief Medical Officer | $784,971.00 | — | 57 | $232,617.00 | 0.45% |
Olivier Danos | Executive Vice President & Chief Scientific Officer | $770,124.00 | — | 68 | $226,348.00 | 0.44% |
Mitchell Chan | Executive Vice President & Chief Financial Officer | $205,311.00 | — | 45 | $39,650.00 | 0.08% |
Jahannaz Dastgir | Clinical Development Lead | — | — | — | — | — |
Ram Palanki | Executive Vice President & Chief Commercial Officer | — | — | 50 | — | — |
Craig Malzahn | Executive Vice President of Product Development & Chief Technology Officer | — | — | 53 | $82,194.00 | 0.16% |
Nina Hunter | SVP of Global Regulatory Strategy and Quality | — | — | — | — | — |
Sarah Thomas | Senior Vice President of Quality | — | — | — | — | — |
Shiva G. Fritsch | Chief Communications & People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$638,336.80
Net Sentiment
$638,336.80
Net selling
Most Active
Simpson Curran
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 5 sells worth $638,336.80 over the last 12 months. That adds up to net selling of $638,336.80. Simpson Curran was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.3% | +41.4% (13yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.3% over three years. Forward estimates point to Revenue at +41.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages RGNX?
REGENXBIO Inc. (RGNX) lists 11 active executives. The top listed executive is Jahannaz Dastgir, Clinical Development Lead.
Are RGNX insiders buying or selling?
Recent insider activity shows net buying of $33.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.